Heart Meeting in Chicago to Test Blood Pressure Limits
Late-breaking trials on intensive blood pressure control, statins, and inflammation are set for the American Heart Association's meeting in Chicago.
Updated on Nov. 6, 2026 in Heart Disease
The American Heart Association's main scientific sessions run November 7 to 9, 2026, in Chicago, with expanded programming beginning November 6. Late-breaking trials on intensive blood pressure control, statins, inflammation-lowering and lipoprotein(a)-lowering therapies are scheduled.
Why it matters
The OPTIMAL studies are expected to fill major gaps left by the SPRINT trial, which excluded ischemic stroke survivors and people with type 2 diabetes. The STREAM trial will provide evidence on whether statin users are put at risk if they discontinue therapy.
The OPTIMAL trials test a systolic blood pressure target below 120 mmHg, starting from a range of 130-180 mmHg. Their results are not yet available, and the outcomes of the scheduled late-breaking trials remain unknown until presentation.
The players
American Heart Association
The American Heart Association is a leading nonprofit organization focused on cardiovascular health research, education and advocacy, and it hosts this annual scientific meeting.
SPRINT trial
The SPRINT trial is a major randomized study of intensive blood pressure control whose exclusion criteria the OPTIMAL studies are designed to address.
The details
OPTIMAL-Stroke enrolls ischemic stroke survivors, and OPTIMAL-Diabetes enrolls higher-risk individuals with type 2 diabetes. The STREAM trial is a randomized noninferiority study of statin discontinuation in older adults without cardiovascular disease, and the ZEUS trial reports cardiovascular outcomes for the interleukin-6 blocker ziltivekimab.
Timeline
November 6, 2026: Expanded AHA programming begins.
November 7-9, 2026: AHA main scientific sessions held in Chicago.
November 7, 2026: OPTIMAL-Stroke and OPTIMAL-Diabetes late-breakers presented.
November 8, 2026: OptimPacing and SUPERIOR trial presentations.
November 9, 2026: ATTAIN-OSA and WATCH-LV trials presented.
Health Landscape
The OPTIMAL studies extend the SPRINT trial, which excluded ischemic stroke survivors and people with type 2 diabetes from its intensive blood pressure control evaluation. Their results could reshape guidance for these higher-risk groups that the earlier trial did not study.
If the OPTIMAL trials show benefit, adults with prior stroke or type 2 diabetes could see blood pressure targets change in future clinical guidance. The STREAM results may also inform whether older adults without cardiovascular disease can safely stop statin therapy.
The takeaway
Patients with blood pressure, diabetes or statin questions should keep their current treatment plans until these late-breaking results are reviewed with their clinicians. Watch for the November 7-9 presentations for the full data.
What happens next
The AHA main scientific sessions take place November 7 to 9, 2026, in Chicago, with the OPTIMAL, STREAM and ZEUS late-breaking trial presentations scheduled across those days.
Further reading
For more background on related treatments, see Heart Disease coverage.
Source note: This article includes information reported by MedPage Today.
